Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.

作者: Kim M Keppler‐Noreuil , Julie C Sapp , Marjorie J Lindhurst , Victoria ER Parker , Cathy Blumhorst

DOI: 10.1002/AJMG.A.36552

关键词:

摘要: Somatic mutations in the phosphatidylinositol/AKT/mTOR pathway cause segmental overgrowth disorders. Diagnostic descriptors associated with PIK3CA include fibroadipose (FAO), Hemihyperplasia multiple Lipomatosis (HHML), Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi, Scoliosis/skeletal and spinal (CLOVES) syndrome, macrodactyly, megalencephaly Megalencephaly-Capillary malformation (MCAP) syndrome. We set out to refine understanding of clinical spectrum natural history these phenotypes, now describe 35 patients somatic mutations. The phenotypic data show that previously described disease entities have considerable overlap, represent a spectrum. While this overlaps Proteus syndrome (sporadic, mosaic, progressive) it can be distinguished by absence cerebriform connective tissue nevi distinct history. malformations were found 15/35 (43%) epidermal 4/35 (11%) patients, lower than Unlike 31/35 (89%) had congenital overgrowth, 35/35 was asymmetric disproportionate. Overgrowth mild little postnatal progression most, while others severe progressive requiring surgeries. Novel findings include: adipose dysregulation present all unilateral is predominantly left-sided, affects extremities more upper progresses distal proximal pattern, most severely affected marked paucity unaffected areas. current are consistent some genotype-phenotype correlation, cannot yet confirmed.

参考文章(47)
John M Graham, Robert Conway, William B Dobyns, Ghayda Mirzaa, PIK3CA-Related Segmental Overgrowth University of Washington, Seattle. ,(2013)
Aspirin, PIK3CA mutation, and colorectal-cancer survival. The New England Journal of Medicine. ,vol. 368, pp. 289- 290 ,(2013) , 10.1056/NEJMC1214189
Vivian Li, Chi Wong, Tsun Chan, Agnes Chan, Wei Zhao, Kent-Man Chu, Samuel So, Xin Chen, Siu Yuen, Suet Leung, None, Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer. ,vol. 5, pp. 29- 29 ,(2005) , 10.1186/1471-2407-5-29
GHAYDA M. MIRZAA, JEAN-BAPTISTE RIVIÈRE, WILLIAM B. DOBYNS, Megalencephaly Syndromes and Activating Mutations in the PI3K-AKT Pathway: MPPH and MCAP American Journal of Medical Genetics Part C-seminars in Medical Genetics. ,vol. 163, pp. 122- 130 ,(2013) , 10.1002/AJMG.C.31361
M Cizkova, M-E Dujaric, J Lehmann-Che, V Scott, O Tembo, B Asselain, J-Y Pierga, M Marty, P de Cremoux, F Spyratos, I Bieche, Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab British Journal of Cancer. ,vol. 108, pp. 1807- 1809 ,(2013) , 10.1038/BJC.2013.164
Kathryn M. Kinross, Karen G. Montgomery, Margarete Kleinschmidt, Paul Waring, Ivan Ivetac, Anjali Tikoo, Mirette Saad, Lauren Hare, Vincent Roh, Theo Mantamadiotis, Karen E. Sheppard, Georgina L. Ryland, Ian G. Campbell, Kylie L. Gorringe, James G. Christensen, Carleen Cullinane, Rodney J. Hicks, Richard B. Pearson, Ricky W. Johnstone, Grant A. McArthur, Wayne A. Phillips, An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. Journal of Clinical Investigation. ,vol. 122, pp. 553- 557 ,(2012) , 10.1172/JCI59309
Douglas A. Levine, Faina Bogomolniy, Cindy J. Yee, Alex Lash, Richard R. Barakat, Patrick I. Borgen, Jeff Boyd, Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers Clinical Cancer Research. ,vol. 11, pp. 2875- 2878 ,(2005) , 10.1158/1078-0432.CCR-04-2142
Jeffrey A Engelman, Liang Chen, Xiaohong Tan, Katherine Crosby, Alexander R Guimaraes, Rabi Upadhyay, Michel Maira, Kate McNamara, Samanthi A Perera, Youngchul Song, Lucian R Chirieac, Ramneet Kaur, Angela Lightbown, Jessica Simendinger, Timothy Li, Robert F Padera, Carlos García-Echeverría, Ralph Weissleder, Umar Mahmood, Lewis C Cantley, Kwok-Kin Wong, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nature Medicine. ,vol. 14, pp. 1351- 1356 ,(2008) , 10.1038/NM.1890